Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Palazestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olema Oncology Shares OP-3136 Phase 1 Data at ASCO 2026
    Olema Oncology Shares OP-3136 Phase 1 Data at ASCO 2026

    21 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/21/3299773/0/en/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    21 May 2026
    Share Share
    Olema Oncology Appoints Prakash Raman, Ph.D., To Board
    Olema Oncology Appoints Prakash Raman, Ph.D., To Board

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3284210/0/en/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Olema Oncology Unveils Palazestrant, OP-3136 Preclinical Data
    Olema Oncology Unveils Palazestrant, OP-3136 Preclinical Data

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187991

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257678/0/en/Olema-Oncology-to-Present-Preclinical-Data-for-Palazestrant-and-OP-3136-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Olema Oncology Reveals 2025 Financial Results
    Olema Oncology Reveals 2025 Financial Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256109/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177971/0/en/Olema-Oncology-to-Present-Trial-in-Progress-Poster-for-Phase-3-OPERA-02-Trial-of-Palazestrant-Plus-Ribociclib-at-SABCS-2025.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.